Antibiotic composition

Abstract

The present invention relates to a new composition designated as AM-1042 or asukamycin. AM-1042 has an antibiotic activity upon Gram-positive bacteria and Eimeria, and its acute toxicity (LD.sub.50 ' ip.) in mice was 48.5 mg./kg. AM-1042 has an excellent therapeutical effect on various infectious diseases caused by a parasite of Gram-positive bacteria and Eimeria. AM-1042 has been confirmed to be distinguishable from known antibiotics such as e.g. amicetin B, azomycin and manumycin. AM-1042 is produced by fermentation of a microorganism belonging to the genus Streptomyces and capable of producing AM-1042. A composition capable of preventing and curing coccidiosis of poultry containing AM-1042 as active ingredient.

Description

Claims

1. A composition AM-1042 having antibiotic activity and represented by the formula: ##STR2##

2. A process for producing ##STR3## which comprises aerobically culturating a microorganism Streptomyces nodosus subsp. asukaensis in a medium until a sufficient amount of said compound is imparted to said medium, and recovering said compound therefrom.

3. The process of claim 2, in which the culturing is effected at a temperature of from 15.degree. to 40.degree. C.

4. The process of claim 2, in which the culturing is effected at a pH of from 6 to 10.

5. The process of claim 2, in which the product is recovered from the culture medium by solvent extraction.

6. A veterinary composition comprising as active ingredient an effective amount for preventing or treating coccidiosis of the compound ##STR4## in association with a physiologically acceptable carrier or excipient.

7. The composition of claim 6, in which the carrier or excipient comprises an edible foodstuff.

8. The composition of claim 6 containing 0.003 to 0.03% by weight of the active ingredient.

9. A method for preventing or treating coccidiosis in an animal subject which comprises administering to said animal subject an effective amount of the compound ##STR5## for preventing or treating coccidiosis as active ingredient in association with a physiologically acceptable carrier or excipient.

10. The method of claim 9 wherein 0.003 to 0.03% by weight of the active ingredient based on weight of the diet is administered to said animal subject.